Editas Medicine, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Editas Medicine, Inc. on September 8, 2021, covering events occurring on September 3, 2021. The filing pertains to corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
The Board of Directors increased its size by one member and appointed Emma Reeve as an independent director, effective September 3, 2021. Ms. Reeve was designated as a Class III director and appointed to the Audit Committee, where she qualifies as an "audit committee financial expert."
Management Commentary and Compensation
Ms. Reeve brings significant financial and operational experience from her previous roles as CFO of Constellation Pharmaceuticals, Inc., and Corporate Controller at PAREXEL International. Her compensation package includes:
- Annual cash compensation of $40,000 for Board service and $7,500 for Audit Committee service.
- Reimbursement for reasonable travel and meeting expenses.
- An option to purchase 13,736 shares of common stock at the closing price on the date of appointment.
- Vesting schedule: One-third of the shares vest in three equal installments on each anniversary of the grant date, subject to continued service.
Ms. Reeve has entered into a standard indemnification agreement with the Company. No other arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Investor Verification Checklist
- Verify the exact closing price of EDIT stock on September 3, 2021, to determine the exercise price of the granted options.
- Confirm the total number of Board seats following this appointment.
- Review the Company's By-Laws regarding Class III director terms and the 2022 Annual Meeting schedule.
- Check subsequent filings for any changes to the Audit Committee composition or financial expert status.